Stock Track | Jade Biosciences Soars 5.45% Intraday on Analyst Price Target Hikes and Upcoming Pipeline Catalysts

Stock Track
05/08

Jade Biosciences (JBIO) stock soared 5.45% during intraday trading on Friday, following a series of positive analyst actions and outlooks for the company's pipeline.

The surge comes after Wedbush significantly raised its price target on Jade Biosciences to $34 from $24 while maintaining its Outperform rating. This represents a substantial increase of approximately 41.7% in the firm's valuation of the stock.

Additional positive sentiment stems from William Blair analyst Matt Phipps reiterating a Buy rating on the stock, citing approaching catalysts including JADE101 data and developments in the company's multi-asset pipeline. These analyst actions highlight growing optimism about Jade Biosciences' future prospects and potential value creation.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10